Vistagen Therapeutics (VTGN) Research & Development (2017 - 2025)
Historic Research & Development for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to $14.2 million.
- Vistagen Therapeutics' Research & Development rose 2581.16% to $14.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $52.0 million, marking a year-over-year increase of 4212.38%. This contributed to the annual value of $39.4 million for FY2025, which is 9665.87% up from last year.
- Per Vistagen Therapeutics' latest filing, its Research & Development stood at $14.2 million for Q4 2025, which was up 2581.16% from $15.9 million recorded in Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' Research & Development peaked at $15.9 million during Q3 2025, and registered a low of $3.9 million during Q3 2023.
- Moreover, its 5-year median value for Research & Development was $9.6 million (2021), whereas its average is $9.3 million.
- As far as peak fluctuations go, Vistagen Therapeutics' Research & Development surged by 32138.07% in 2021, and later tumbled by 7255.32% in 2023.
- Over the past 5 years, Vistagen Therapeutics' Research & Development (Quarter) stood at $7.8 million in 2021, then decreased by 11.89% to $6.9 million in 2022, then plummeted by 33.81% to $4.5 million in 2023, then soared by 149.17% to $11.3 million in 2024, then rose by 25.81% to $14.2 million in 2025.
- Its Research & Development stands at $14.2 million for Q4 2025, versus $15.9 million for Q3 2025 and $11.7 million for Q2 2025.